{
    "ticker": "BTAI",
    "name": "BioXcel Therapeutics, Inc.",
    "description": "BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on advancing the development of innovative therapies for neurodegenerative diseases and other disorders. Founded in 2017 and headquartered in New Haven, Connecticut, the company is dedicated to harnessing artificial intelligence and machine learning to accelerate drug discovery and development. BioXcel's lead product candidate is BXCL501, a sublingual film formulation of dexmedetomidine designed to treat agitation in patients with neurodegenerative diseases and other conditions. The company aims to address significant unmet medical needs through its proprietary AI platform, which identifies and optimizes potential therapeutic candidates. With a strong commitment to patient-centric solutions, BioXcel Therapeutics is working to transform the treatment landscape for serious health conditions, improving the quality of life for patients and their families. The company envisions a future where technology and science converge to create novel therapies that enhance patient outcomes and drive better healthcare solutions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New Haven, Connecticut, USA",
    "founded": "2017",
    "website": "https://www.bioxceltherapeutics.com",
    "ceo": "Vimal Mehta",
    "social_media": {
        "twitter": "https://twitter.com/BioXcelThera",
        "linkedin": "https://www.linkedin.com/company/bioxceltherapeutics/"
    },
    "investor_relations": "https://investors.bioxceltherapeutics.com",
    "key_executives": [
        {
            "name": "Vimal Mehta",
            "position": "CEO"
        },
        {
            "name": "Ravi S. Ahuja",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "BXCL501"
            ]
        }
    ],
    "seo": {
        "meta_title": "BioXcel Therapeutics, Inc. | Innovative Neurodegenerative Disease Therapies",
        "meta_description": "Learn about BioXcel Therapeutics, Inc., a biopharmaceutical company leveraging AI to develop transformative therapies for neurodegenerative diseases.",
        "keywords": [
            "BioXcel Therapeutics",
            "Biotechnology",
            "Neurodegenerative Diseases",
            "BXCL501",
            "Pharmaceuticals",
            "AI in Drug Development"
        ]
    },
    "faq": [
        {
            "question": "What is BioXcel Therapeutics known for?",
            "answer": "BioXcel Therapeutics is known for developing innovative therapies using artificial intelligence for neurodegenerative diseases."
        },
        {
            "question": "Who is the CEO of BioXcel Therapeutics?",
            "answer": "Vimal Mehta is the CEO of BioXcel Therapeutics, Inc."
        },
        {
            "question": "Where is BioXcel headquartered?",
            "answer": "BioXcel is headquartered in New Haven, Connecticut, USA."
        },
        {
            "question": "What is BioXcel's lead product candidate?",
            "answer": "BioXcel's lead product candidate is BXCL501, aimed at treating agitation in patients."
        },
        {
            "question": "When was BioXcel Therapeutics founded?",
            "answer": "BioXcel Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "NVAX",
        "ADMA",
        "CRIS",
        "SNAP"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "MRNA"
    ]
}